Cloud Hosting

Artificial Intelligence (AI) is probably one of the most hypedor over-hypedbuzzwords in the technology industry. What does it really mean? Is it a sci-fi trope, a marketing term, something that could actually help humanity, a new dawn, a threat or all of the above? Researcher Konstantinos Sgantzos helps clear it up in this weeks episode of The Bitcoin Bridge.

Konstantinos is probably one of the best people to ask about all this. As a researcher with the department of Computer Science & Bioinformatics at Greeces University of Thessaly, he has studied the topics of data analysis and machine learning for many years. He also recently collaborated with Ian Grigg on a paper describing how a general artificial intelligence could use blockchain data to help guarantee its integrity.

Hes also been known to say AI promises are often over-hyped, and that it doesnt involve actual, general intelligence in the sense humans have it. Its more analysis of information or statistics on steroids, focusing on single tasks rather than trying to make broad decisions across a variety of issues.

In this episode we go over some of the promises AI has given us: self-driving cars, the ability for computers to understand human conversations, economic analysis, and such. It all ties in to the concept of Big Data and perhaps the most important aspect of that is data integrity. No matter how great an analytical machine is, its decisions are only as good as the information it receives. To make sure this information is secure, reliable and resistant to manipulation, we need a ledger capable of recording and verifying large amounts of data. Only the BSV blockchain has this kind of capability.

We also look at what AI actually is, and talk about some developments over the past few decades that made current and future systems possible. For researchers and programmers there have been surprises along with disappointments, unexpected challenges and others that were entirely predictable.

AI is an important topicnot only for the changes it could bring to our lives, but in keeping our expectations of its capabilities realistic. Theres a danger we could put too much trust in it, make assumptions about how smart a system actually is, and see AI decisions as superior to human intelligence thanks to its mystique (and a lot of sci-fi movies).

On that topic, are there any movies or stories out there that describe AI in a realistic way? Konstantinos answer to this might surprise a few people. Watch the full episode above to find out more, and if youre interested, discover what resources are available to further your knowledge.

The Bitcoin Bridge comes out every Mondaysubscribe to the CoinGeek YouTube channelso you dont miss an episode, and alsocheck out previous episodes on Streamanity.

Watch: CoinGeek Zurich panel, AI Machine Learning & Blockchain Views from Academics & Researchers

New to Bitcoin? Check out CoinGeeksBitcoin for Beginnerssection, the ultimate resource guide to learn more about Bitcoinas originally envisioned by Satoshi Nakamotoand blockchain.

See more here:
The reality of artificial intelligence: Konstantinos Sgantzos talks to The Bitcoin Bridge - CoinGeek

Read More..

Sean Lane, the CEO of health care artificial intelligence firmOlive AI, believes the future of the U.S.workforce is a combination of human labor and artificial intelligence people and technology working side-by-side. Lane wants to see Olive have a role in that force.

The Columbus-based software company, which grew exponentially during the pandemic, tripling to 600 employees, continues to expand, and it closed a $400 million funding round July 1 andwas valued at $4 billion.

In an interview with the Dispatch, Lane broke down the firm's somewhat complex business, talked about the meaning behind the name "Olive," and described the brightfuture he sees in Columbus tech.

Dispatch: What Olive does is pretty high-tech, and its a little complicated. In laymans terms, could you break down what Olive does, and what problems the company is working to solve?

Lane: First and foremost, health care doesnt have the internet. Thats the biggest problem. You see that every time you go to a doctors office you have to fill out the same form, every single time. Its like health care doesnt know who you are. Thats because the systems arent connected and they dont talk to each other and the software doesnt talk to each other. Olive is really automation that connects all of those things together. We use artificial intelligence to do it, to create this workforce of AI (artificial intelligence) workers, that provide automation to connect everything together, to take on a lot of the administrative burdens, to work on these workflows inside health care, so that ultimately, the experience of health care is much more like what you get in other areas that have the internet, from shopping to hotels or anything else.

AI in Columbus:: Path Robotics CEO wants Columbus to be 'next big mecca' for robots

Could you describe Olives customer base for me? Our customer base today is about 80% health systems around the country. We have about 900 hospitals as our customers, and then also insurance companies, health plans. That constitutes the other portion of our customer base.

Whats the meaning behind the name Olive? We decided that, to do this, we wanted to create an artificial intelligence, which means we wanted it to be difficult to distinguish from a human as it is working. Olive, herself, takes on the persona, so we picked a persons name. The cool thing about Olive is its a thing and its a persons name, but it also has the word live in it. You say it 'all of'the time without realizing it: Because all of is the same as Olive. The O is a pretty iconic symbol, and really, these workflows are like circuits, theyre these circles and loops. Youll see the circular kind of name in a lot of things we do.

Ive noticed it in just reading about the company: Olive is kind of her own person. Yeah, thats right. We wanted Olive to take on a persona, like part of your team. Olive is a part of your team. Its hospitals and at these insurance companies providing automation. We think that theres a new workforce, for the future, and that workforce contains humans and AI workers. Olive is one of those AI workers. The way we think about that is, health systems in the future are going to have AI workers, an AI workforce. Olive is just one of those employees.

The Dispatch has previously covered this, but could you tell me a little bit, in your own words, about The Grid and your workforce model at Olive as we sort of emerge from the pandemic? We had always believed that the greatest companies in the world were built in one building, and that that was kind of the way to do it. Once the pandemic happened, and we were out of the building, a lot of those assumptions basically didnt hold any water. They werent true, and we kind of invalidated assumption after assumption about being in one building. We decided that the best approach for us, moving forward, was to get rid of the word remote, get rid of the word work from home, and allow people to work from wherever theyd like. Wed only have two statuses: On the grid and off the grid. So youre either working or youre not working working from home is not less of a status than working in an office. We adopted this new model, we then started recruiting around the country. And you know, it worked. The great thing about it is, it allowed us to scale super, super fast. We needed to hire a ton of people, and really the only way we could have done it was with adopting The Grid.

The Grid at Olive AI:Olive is hiring big time, and most of its new employees don't live in Columbus

Big news came at the start of the month when Olives most recent valuation had it at $4 billion. Could you describe what this means for the company? Its another milestone in our growth. The reality is, our company is just getting started. Were close to 1,000 customers, close to 1,000 employees. Weve raised close to $1 billion dollars. But the reality is, its still the very, very early stages of this company. We have so much to do, so many products to build, so many new customers to expand to. Its a great milestone because it just proves that what were doing is important to the world, and specifically, to the health care industry.

Is there anything else that you wanted to talk about? I would just say that we are trying to build a technology company for health care that can invest significant resources into R&D (research and development) the same way that tech companies do for other industries. Health care is not going to be the laggard anymore, health care is not going to take the seconds of technology from other industries. This is the moment for health care to be the leader in technology, the same way the defense industry led the creation of Silicon Valley, the same way the space race led to a lot of the creation, again, of Silicon Valley. Health care innovation can lead to the creation of something really special. Columbus is one of the best places in the country to grow a startup, as weve shown. Its not that Silicon Valley is going away. Its just getting bigger, and the idea of Silicon Valley now exists in Columbus, Ohio.

sdonaldson@dispatch.com

@SarahEDon

See the original post:
Columbus-based health care software startup Olive is valued at $4 billion. So what exactly does the company do? - The Columbus Dispatch

Read More..

Image depicting Sun's solar cycles.

Researchers are using artificial intelligence (AI) techniques to calibrate some of NASA's images of the Sun. Launched in 2010, NASA's Solar Dynamics Observatory (SDO) has provided high-definition images of the Sun for over a decade.

The Atmospheric Imagery Assembly, or AIA, is one of two imaging instruments on SDO and looks constantly at the Sun, taking images across 10 wavelengths of ultraviolet light every 12 seconds.

This creates a wealth of information of the Sun like no other, but like all Sun-staring instrumentsAIA degrades over time, and the data needs to be frequently calibrated, NASA said in a statement.

To overcome this challenge, scientists decided to look at other options to calibrate the instrument, with an eye towards constant calibration.

Machine learning, a technique used in artificial intelligence, seemed like a perfect fit. To start, the team would teach the algorithm what a solar flare looked like by showing it solar flares across all of AIA's wavelengths until it recognised solar flares in all different types of light.

Once the programme can recognise a solar flare without any degradation, the algorithm can then determine how much degradation is affecting AIA's current images and how much calibration is needed for each.

"This was the big thing. Instead of just identifying it on the same wavelength, we're identifying structures across the wavelengths," said Dr Luiz Dos Santos, a solar physicist at NASA's Goddard Space Flight Center in Greenbelt, Maryland, and lead author on the paper published in the journal Astronomy & Astrophysics.

"It's also important for deep space missions, which won't have the option of sounding rocket calibration. We're tackling two problems at once."

Since AIA looks at the Sun in multiple wavelengths of light, researchers can also use the algorithm to compare specific structures across the wavelengths and strengthen its assessments.

As machine learning advances, its scientific applications will expand to more and more missions.

"For the future, this may mean that deep space missionswhich travel to places where calibration rocket flights aren't possiblecan still be calibrated and continue giving accurate data, even when getting out to greater and greater distances from Earth or any stars," said NASA.

**

The above article has been published from a wire agency with minimal modifications to the headline and text.

Continued here:
Scientists Look Up To Artificial Intelligence Techniques to Improve Solar Data from the Sun | The Weather Channel - Articles from The Weather Channel...

Read More..

HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions.

InSilico Solutions is a world-class bio-informatics and artificial intelligence innovator with a long standing collaborative relationship with its clients at MD Anderson Cancer Center, Johns Hopkins School of Medicine, and the National Cancer Institute.

With this acquisition, Kiromic will bring in-house a team of experts in bioinformatics and AI in order to lengthen its lead in the race for an AI technology with the capability to select the optimal bio-markers needed for cutting edge immunotherapeutics such as CAR-T cell therapy.

Many CAR-T developers are still developing their CAR-T with biomarkers from decade old target libraries with known poor clinical outcomes.

Chief Executive Officer of Kiromic, Maurizio Chiriva-Internati, DBSc, PhDs, commented

We are pleased to have officially closed this long awaited acquisition of InSilico Solutions.

The InSilico Solutions is another testament to our commitment to developing the very best possible CAR-T. And the very best CAR-T will start with having the best possible bio-markers by employing cutting edge bio-informatics and AI technologies.

Our CAR-T will be outpatient, off-the-shelf allogeneic.

The amount of information that oncologists and scientists gather from cancer patients continues to grow exponentially.

The number of scientists and the time those scientists have to analyze those billions of data point have not grown exponentially.

It makes sense that bioinformatics and artificial intelligence are brought to bear on the tasks of going through the mountains of data to select biomarkers in a few hours which would have required decades of human labor to do.

Best bio-informatics and AI.

Better biomarkers.

Better Manufacturing.

Better CAR-Ts.

Better Clinical Outcomes.

Chief of BioInformatics and Research Computing Officer, Michael Ryan, PhD commented :

Over the past 3 years we have had an amazingly productive collaboration with Kiromic.

Together we produced a highly effective system that allows Kiromic to identify the needles in the haystack of genomic data small sections of protein that are specific to the surface of cancer cells and that can be targeted by immunotherapy.

The entire InSilico staff is extremely energized by the acquisition by Kiromic.

We believe we can have an immediate, significant impact on accelerating delivery of effective treatment to patients.

Our next focus will be on utilizing AI methods to optimize response to allogeneic T cell therapy.

In particular, we are developing models using WGS, RNASeq, scRNASeq, cytrometry, and cytokine panels to assist in selecting donor T cells with the strongest therapeutic potential.

Similar data from clinical trials will be used refine our understanding of efficacy and toxicity to improve treatment protocol and patient selection.

We will continually evaluate, implement, and improve our industry leading systems that will accelerate therapeutic development, manufacturing, and clinical testing of Kiromics off-the-shelf allogeneic CAR-T for solid tumors.

Chief Medical Officer of Kiromic, Scott Dahlbeck, MD commented:

World-wide, patients with advanced cancer conditions are in great need of effective treatment solutions that can be added to the clinical armamentarium of medical providers.

However, in order to achieve significant gains in patient survival, innovative discoveries in biomarker discovery, selection, and validation are critical to facilitate the development of the next generation of immunotherapeutics that can truly make a difference.

The acquisition of InSilico Solutions is a major step forward in this process, and we are looking forward to the breakthroughs that will result from this expansion of Kiromics AI capabilities and subsequently its CAR-T.

Chief of Strategy and Innovation Officer, Mr. Gianluca Rotino commented:

The acquisition of InSilico will allow significant advancement in the use of computational technologies throughout the development process, from discovery to manufacturing and in clinical trials.

This places Kiromic among the pioneers in innovative cell therapy and makes the upcoming clinical trial a critical milestone not only for the company, but for all the Cell Therapy Space.

Under the agreement terms, Kiromic acquires InSIlico through a stock-swap operation, hiring the entire staff of InSIlico and their material and immaterial assets.

The deal was followed up by the Strategy and Corporate Development department of Kiromic Biopharma

BEVILACQUA LLP served as Legal Counsel.

ThinkEquity served as financial advisors. ThinkEquity, a division of Fordham Financial Management, Inc.

Chief Financial Officer, Mr. Tony Tontat commented:

InSilico Solutions was a great find for the company 3 years ago when the collaboration started.

It's an even better find today with the closing of this acquisition.

InSilico in-house will mean that our bio-informatics department will have the continuous attention of developers as new developments evolve.

The InSilico acquisition will not impact the company's cash runway post the recent follow-on financing which closed on July 2021.

About InSilico Solutions

http://insilico.us.com/

Overview

InSilico Solutions is a bioinformatics company with a stellar 10-year track record of developing innovative software for cancer researchers.

InSilico staff includes an even mix if PhD scientists and senior engineers who specialize in building applications for analysis of diverse, large-scale genomics data.

InSilico's skills in machine learning, modeling, visualization, and intuitive interface design allows them to present complex data to researchers in an interpretable fashion, laying the groundwork for faster and more thorough discovery.

InSilico's Tools

http://insilico.us.com/services.html

InSilico designs and develops sophisticated analytical software tools that assist in extracting biological insights from vast quantities of genomic data.

InSilico builds custom bioinformatics applications that perform complex analysis but that provide users with intuitive, visual interfaces that make exploring the data much easier.

Our applications are robust and user friendly.

InSilico has experience developing custom tools for a variety of different types of data:

-- Next Generation Sequencing (DNA and RNASeq)

-- Microarrays (Expression, Methylation, Copy Number, SNPs)

-- 3D Protein Structures

External Data (UCSC Tracks, Ensembl, NCBI, TCGA, dbSNP, 1000 Genome, COSMIC, etc)

InSilico employs state of the art design methods, code reviews, formal documentation, and automated testing to deliver high quality software applications.

InSilico's Data Interface

http://insilico.us.com/portfolio.html

In collaboration with Dr. Weinstein's BCB Group at MD Anderson, InSilico developed a Next Generation Heat Map Tool with an advanced JavaScript architecture utilizing WebGL for accelerated graphical rendering.

The NGCHM tool handles very large-scale clustered heat maps and brings them to life with pan, zoom, and link-out features delivering a strong platform for exploratory genomics discovery.

InSilico data analytic tools can be run on a web server or stand-alone and has been packaged as a Galaxy tool and a Docker image for easy installation and use in a variety of environments including cloud-based pipelines.

The small square shows in detail the expression of 50 genes on 50 The Cancer Genome Atlas (TGCA) samples.

Smoker (level) and Age.

The genome cancer atlas (TCGA) molecularly characterized over 20,000 primary cancer and matched normal samples spanning 33 cancer types.

TCGA generated over 2.5 petabytes of genomic, epigenomic, transcriptomic, and proteomic data.

InSilico data analytic tools like the above help to navigate in these data.

InSilico's World-Class Collaborations

InSilico has a long-term collaborative relationship with its clients at MD Anderson Cancer Center, Johns Hopkins School of Medicine, and the National Cancer Institute.

Through these collaborations, InSilico has developed many published, open-source cancer research tools that are in broad use by multiple research communities. The team plans to continue these highly productive relationships post-merger.

InSilico has been a fantastic partner and provided the engineering muscle behind many of our popular cancer research tools.

Their disciplined, rapid development approach combined with strong skills in software architecture, machine learning, and interface design have been invaluable to our work, said Dr. Rachel Karchin, Professor, Johns Hopkins University. Institute for Computational Medicine, Department of Biomedical Engineering, Department of Oncology, Department of Computer Science.

InSilico and Kiromic CancerDiff

Kiromic has engaged InSilico to develop several of its critical systems for therapeutic target selection including CancerDiff, and the automated Protein Research Assistant.

The algorithms identify tumor specific isoforms with targetable peptides on surface proteins with low probability of off target effects.

Target selection transcends tissue of origin to identify cross-tumor sub-populations with shared, targetable molecular characteristics.

Research functions automate, improve, and shorten previously labor-intensive steps of deep dive target investigation.

See Kiromic's AACR 2021 Poster: CancerDiff by Insilico (Link to AACR 2021 Press Release)

Mesothelin isoform 2 is a novel target for allogenic CART cell therapy in solid tumors

Kiromic 3D, isoform prediction engine which examines billions of data points to select the best targets.

InSilico and Kiromic's Bioinformatics

The InSilico and Kiromic teams have proven to work effectively together in a highly synergistic manner.

Merging InSilico into Kiromic as its Bioinformatics Department will allow the formation of a fully integrated organization with enhanced capability to apply the latest machine learning methods to reduce therapy design timelines and more efficiently deliver effective treatment to patients.

InSilico's Publications

http://insilico.us.com/publications.html

Previous Kiromic Press Release

June 16, 2021: KIROMIC BIOPHARMA PROVIDES UPDATE ON IND FILINGS ON ITS OFF-THE-SHELF, ALLOGENEIC CAR-T FOR SOLID TUMORS

About Kiromic

Kiromic BioPharma, Inc. (Nasdaq: KRBP) is an emerging clinical stage biopharmaceutical company focused on advancing the cellular therapy field, for solid tumors utilizing a state-of-the-art artificial intelligence (AI) platform focused on unleashing the power of the patients own immune system to fight cancer.

Kiromics pipeline development is leveraged through the Companys proprietary target discovery Artificial Intelligence engine called "DIAMOND." Kiromic's DIAMOND is big data science meeting target identification, dramatically compressing the man-years and the millions of drug development dollars needed to develop a live drug.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as anticipate, believe, contemplate, could, estimate, expect, intend, seek, may, might, plan, potential, predict, project, target, aim, should, "will would, or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our companys current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled Risk Factors in the Companys annual report on Form 10-K for the most recently completed fiscal year and subsequent reports filed after the date of the annual report with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and our company undertakes no duty to update such information except as required under applicable law.

Read this article:
Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on...

Read More..

Campari, the iconic Italian aperitif, announces the return of Campari Red Diaries with Fellini Forward; a pioneering project, in collaboration with Fellini's family and former colleagues, exploring the late Federico Fellini's creative genius using new technology and machine learning to emulate the works of one of the greatest filmmakers of all time in a new and unique short film set in Rome. A one-of-a-kind documentary following the process will have its world premiere at the Venice Film Festival on September 7th and North American premiere as a Partner Presentation at the 59th New York Film Festival. The documentary will then be released on a subscription video on demand (SVOD) platform in select markets, inviting consumers to explore the future of cinema and creativity.

Since its creation over 160 years ago, Campari has pushed the boundaries of creativity to go beyond the norm, unlocking the passions and talents of artists across different fields in the path to creation. From world famous names to emerging talent, the relationship between Campari and the arts, especially cinema, has been solidified over the years. Having worked on an advertisement with Federico Fellini, for one of his few brand collaborations in 1984, this year's Campari Red Diaries Fellini Forward continues the brand's legacy, marrying both creativity and innovation within the cinema industry with the most forward-looking technology. Thanks to a team of experts from production and innovation studio UNIT9, dedicated Artificial Intelligence tools were explored and developed to unearth Federico Fellini's creative genius in ways that had never been attempted until now. Francesca Fabbri Fellini, Fellini's niece, was involved in the project from the start, together with Directors Zackary Canepari and Drea Cooper (documentary), Maximilian Niemann (short film) and a robust crew, introducing them to some of Fellini's key colleagues, sharing counsel and first-hand knowledge of her uncle, as well as contributing to the casting, costume design and script writing for the short film. This seamless collaboration between human and Artificial Intelligence showcases how the sentimental and the rational, the emotional and the data-driven can come together to create a brand new piece of art.

On the project Francesca Fabbri Fellini comments: "My Uncle Federico was original in his ways of representing life using dream-like elements as his means of communication. I think a project like this is a perfect way to honor his legacy. Though he took much inspiration from his past, he was always looking ahead. A similar approach was taken for this project with Campari; it is rooted in heritage yet is futuristic with the use of Artificial Intelligence."

Throughout the process, original members of Fellini's crew were involved and consulted, providing key insights on the Maestro's oeuvre. This included Fellini's camera operator Blasco Giurato (The Clowns, 1970), his three-time Oscar winning set designer Dante Ferretti (Orchestra Rehearsal, 1978; City of Women, 1980; And the Ship Sails On, 1983; Ginger and Fred, 1986; The Voice of the Moon, 1990) and Luigi Piccolo, Director of Sartoria Farani, a renowned Italian tailor shop which holds restored costumes from some of Fellini's greatest films including (Satyricon, 1969; The Clowns, 1970; Amarcord, 1973). Each member was conferred to define what elements in the endeavor could be perceived as Felliniesque. The result culminated in a fascinating short movie, set in the heart of Rome, that explores Fellini's life and dreams with distinctive, signature characters and arrangements throughout.

Documentary Director duo ZCDC, Zackary Canepari and Drea Cooper, captured the making of this short film, inviting significant experts of Artificial Intelligence and creativity Marcus du Sautoy and Dr. Emily L. Spratt to join the set to share their opinion on the ground-breaking initiative. Hava Aldouby, Art Historian and Fellini expert, as well as Anita Todesco, Galleria Campari curator were also consulted, providing an eclectic view on the subject, sparking debate around the role Artificial Intelligence can play in creativity and beyond.

Marcus du Sautoy, Artificial Intelligence & Creativity Expert says: "We should see Artificial Intelligence as an extraordinary collaborator; it's a new tool, like Galileo getting a telescope and being able to see further into the universe than ever before. Artificial Intelligence is a tool that allows us to analyze data at a scale that humanly, we can't possibly match. In this project, one of the Artificial Intelligence's greatest accomplishments was taking Fellini's films and analyzing each, frame by frame. Using this tool in the creative industry is an extremely exciting step forward and will assist in finding ideas that we are currently missing - Artificial Intelligence can help us break our own molds to create new stories"

Through the Campari Red Diaries 2021 Fellini Forward project, Campari aims to continue the legacy of innovation and creativity set out by its founders, inspiring future generations and creatives across the globe to unlock their own passions. Campari has also created a unique apprentice program with students involved in the Fellini Forward futuristic projects from all over the world including Centro Sperimentale di Cinematografia (CSC) in Italy, The American Film Institute in Los Angeles and The International Academy of Audio-visual Sciences (CSIA) in Switzerland to explore the creative genius of Fellini, using the Artificial Intelligence technology and speaking to key members of the film crew at each stage of production to see first-hand how human minds collaborated with Artificial Intelligence to create the short film.

Jean Jacques Dubau, Head of Marketing, Campari Group comments: "We are so pleased to be back with our Campari Red Diaries project in 2021, honoring the creative legacy of one of the greatest filmmakers of all time, Federico Fellini. At Campari we look to push the boundaries of innovation in creativity and have done so for over 160 years, with a view to leave a lasting legacy for future generations inviting them to explore their Red Passion, the urge of creativity that cannot be ignored. We hope that the endeavor of Fellini Forward will transport people in the past, and in the future, exploring creative genius in brand new ways, while enjoying an iconic Campari cocktail such as the Negroni."

Please follow Campari's social media channels for further information @CampariOfficial @CampariUSA.

https://www.youtube.com/EnjoyCampari; https://www.facebook.com/CampariUS;

https://www.instagram.com/campariusa/; https://twitter.com/campari

#Campari #RedPassion #RedDiaries #FelliniForward

To enjoy a sneak peek of Fellini Forward, view the teaser video on YouTube here.

Visit the Campari website: http://www.campari.com

Photo Credit: Courtesy of Campari

Follow this link:
CAMPARI Creates Short Film with Artificial Intelligence Inspired by the Genius of Fellini - Broadway World

Read More..